2014 Archived Content

Cambridge Healthtech Institute’s Inaugural

Protein & Antibody Engineering

April 1-2, 2014 | Shanghai Marriott Hotel Pudong East | Shanghai, China

 
 

7:30 am Registration and Morning Coffee

 

8:50 Chairperson’s Opening Remarks

LeiZhengLei Zheng, M.D., Ph.D., Assistant Professor, Oncology, John Hopkins University School of Medicine, USA



 

GENERATING ANTIBODIES AGAINST GPCR 

9:00 Novel GPCR-Targeting Therapeutic Antibodies

Anke Kretz-Rommel, Ph.D., Vice President, R&D, NA, RuiYi, Inc., USA

While many companies have successfully generated mAbs against chemokine receptors, the vast majority of GPCRs has not been addressed with mAbs due to the difficulty of obtaining pure GPCR protein in the proper conformation. RuiYi’s core technology has now successfully been used to select a panel of mAbs against two class A GPCR receptors for the treatment of fibrotic diseases. mAbs obtained include many binders to extracellular loops of fairly short length, bind to conformational epitopes and do show functional activity, resulting in mAbs with desired therapeutic properties.

Case and Unpublished Icon Combo

9:30 Challenging Targets: Generating High-Quality Antibodies against G-Protein Coupled Receptors

StephanieUrlingerStefanie Urlinger, Ph.D., Director, R&D, Discovery Alliances Technologies,
MorphoSys AG, Germany

The generation of antibodies of therapeutic potential against GPCRs is a technically challenging task. We have built up a broad platform of techniques that allow us to reliably generate specific and functionally active antibodies against GPCRs. We will show case studies for anti-GPCR antibody generation and detailed characterization of the antibodies.

10:00 Q&A

10:15 Coffee Break

ANTIBODY DISCOVERY AND CLINICAL DEVELOPMENT 

11:00 Implementing Systems Immunology Methods for Monoclonal Antibody Discovery

SaiReddySai Reddy, Ph.D., Assistant Professor, Department of Biosystems Science and Engineering, ETH Zurich, Switzerland

We have developed novel methods for monoclonal antibody discovery based on systems biology methods. Specifically, we now use the Illumina mi-Seq platform to obtain large datasets of antibody variable genes from immunized mice. We have developed bioinformatic software that is capable of processing sequence data and provide predictions for antigen-specific clones. Finally we use gene synthesis technology for recombinant expression and validation of monoclonal antibody specificity.

Case Study Icon

11:30 Clinical Development of Tanibirumab and Its Next Generation Therapeutics

YooJinSanJin-San Yoo, Ph.D., CEO, President & Founder, PharmAbcine, Korea

Tanibirumab is anti-KDR neutralizing fully human IgG with cross species cross reactivity which is unique. Its Phase I study is completed and we are evaluating all kinds of data we already got and we will get. From the preliminary data, Tanibirumab has no MTD and DLT up to 24mg/kg. We observed several stable disease patients among progression disease patients. In contrast to Ramucirumab, VEGF-Trap, Avastin, and other VEGF/KDR antagonist, Tanibirumab hasn’t cause any hemorrhage, bleeding and hypertension. We are preparing for phase II study with recurrent GBM patients and exploring other indication.

Origene12:00 pm Evaluate Diagnostic Antibody Specificity by Using High Density Protein Microarray Technology

Ma-DonghuiDonghui Ma, Ph.D., CSO, OriGene-WuXi & Senior Vice President, Immunology, OriGene

Sensitivity and specificity are the two key features for a good diagnostic antibody. High density protein microarray technology is the best technology platform for antibody specificity evaluation. Here we showcase a novel protein microarray technology to evaluate target specificity for a couple of commonly used IHC diagnostic antibodies. Our data suggested that cross-reactivity is one of the reasons to create off-target staining. We will also introduce UltraMAB, the Ultra-specific monoclonal antibodies for anatomic pathology application.

12:30 Networking Luncheon

 

1:40 Chairperson’s Remarks

MitkoDimitrovDimiter Dimitrov, Ph.D., Senior Investigator, Center for Cancer Research, NCI, National Institutes of Health, USA

 



ANTIBODIES FOR CANCER IMMUNOTHERAPY 

Unpublished Data Icon

1:45 New Focus of Antibody-Based Therapeutics: Targeting Tumor Microenvironment

LeiZhengLei Zheng, M.D., Ph.D., Assistant Professor, Oncology, John Hopkins University School of Medicine, USA

Rapid developments in antibody target discovery and antibody-based therapeutics have revolutionized cancer therapy. The tumor microenvironment is recognized as an important target for cancer therapy. Newly developed monoclonal antibodies targeting immune checkpoint signals in the tumor microenvironment are promising in overcoming the barriers to effective immunotherapy for gastrointestinal cancers. Appropriate combination of different therapeutic strategies is still a key to the success of cancer immunotherapy.

 

2:15 Therapeutic Antibodies Against Human Insulin-like Growth FactorsUnpublished Data Icon 

Qi ZhaoQi Zhao, Ph.D., Associate Professor, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences

The insulin-like growth factors (IGF), IGF-I and IGF-II, have been implicated in the growth, survival, and metastasis of a broad range of neoplasm. We have identified novel human mono and bispecific antibodies, which exhibited high affinity binding to human IGF-I, II. They potently inhibited both IGF-I, II-induced phosphorylation of IGF1R as well as IGF-II-induced phosphorylation of the insulin receptor (IR) in tumor cells. Studies in human cancer models suggested that these antibodies have promising preclinical activity against a broad spectrum of human neuroblastoma. The clinical development of this agent is planned.

2:45 Targeted Tumor Immunotherapy through Engineered AntibodiesUnpublished Data Icon 

Xiaoxiao Wang, Ph.D., Associate Director, AlphaMab Co., Ltd., PR China

With novel mechanism discovered for monoclonal antibodies in hand, we have designed a series bispecific antibodies and antibody-protein hybrid. Those molecules have been constructed using the proprietary Fc heterodimeric technology developed in Alphamab. In vitro and in vivo efficacy data indicate that those novel molecules have broad application in tumor treatment.

PerkinElmer3:15 From Discovery to QC: Enabling Solutions for Biotherapeutic Research and Development

Martina Bielefeld SevignyMartina Bielefeld Sevigny, Ph.D., Vice President  & General Manager, PerkinElmer LST

Biologics, being complex bio-molecules, require a wide spectrum of methods to characterize them in order to assure consistent safety and efficacy. In this presentation we will discuss novel technologies based on microfluidics and AlphaLISA showing breakthrough data from detection of residual process contaminants to fast determination of glycosylation patterns.


GYROS3:30 High Throughput Bioanalytics to Support Impurity Testing: Improving Efficiency and Productivity
Karolina Österlund, Manager Field Application Specialists, EU and Asia, Gyros AB 


 

3:45 Refreshment Break  

 

NOVEL SCAFFOLDS, ANTIBODY DOMAINS & FRAGMENTS 

4:15 Engineered Human Antibody Domains, Fragments and Full-Size IgG1 against Cancer and Viruses

MitkoDimitrovDimiter Dimitrov, Ph.D., Senior Investigator, Center for Cancer Research, NCI, National Institutes of Health, USA

The work in our group in three major directions will be discussed: 1) engineered antibody domains and fragments as related to the development of exceptionally potent inhibitors of HIV-1 and tools for its eradication, 2) IgG1-based candidate therapeutics against cancer with an emphasis on novel concepts and evaluation in animal models, and 3) full-size IgG1s against emerging and biodefense-related viruses including henipaviruses and coronaviruses, especially for prophylaxis and therapy of humans.

Unpublished Data Icon

4:45 Human VH Antibody Fragments from a Transgenic Mouse Platform

YuminYumin Teng, Ph.D., Head, Molecular Biology, Crescendo Biologics, Ltd., United Kingdom

Single domains are the smallest, most robust antibody fragments and as such have advantages for tissue and tumour penetration, engineering of multivalent products, topical delivery and simple manufacture. The Crescendo Mouse harnesses the benefits of in vivo maturation while generating heavy chain antibodies as a source of fully human VH. Data from multiple immunisations and discovery programmes will be used to illustrate the ability of the platform to rapidly generate a high diversity of potent leads with excellent biophysical properties.

Unpublished Data Icon

5:15 Optimization on Antibody CH2 Domain for Reduction of Aggregation: Implication for New Scaffold Design 

GongRuiRui Gong, Ph.D., Professor, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, PR China

Antibody CH2 domain was proposed as novel scaffold for development of novel nanoantibodies as therapeutic candidates. However, isolated CH2 tends to aggregate. We found removal of seven residues at N-terminal in CH2 could decrease the aggregation tendency. Based on computer analysis, several aggregation prone regions in CH2 were also identified, which could be mutated to increase the aggregation resistance. Reduction of aggregation in CH2 can bring advantages in library construction and binder selection.

5:45 Welcome Reception in the Exhibit Hall with Poster Viewing

 


Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 


Register Now 


Download 2015 Brochure
2015 ABA Brochure Icon
 

Premier Sponsor
Protein Simple 


View All Sponsors > 

View Media Partners > 

Promote your company’s latest technology and/or solution at PEGS CHINA. A limited number of agenda presentations (as part of a sponsorship package), exhibit space, branding, and promotional opportunities are available.


Track 1

Protein Engineering 

Track 2

Phage & Yeast Display 

Track 3

Antibody-Drug Conjugates 

Track 4

Characterization of Biotherapeutics